NantKwest Inc., a biotechnology company launched by Los Angeles businessman Patrick Soon-Shiong, raised $39 million in a private placement by its chairman and chief executive to advance a natural killer cell treatment for cancer.
The publicly traded company announced March 25 that Soon-Shiong had exercised warrants and options to raise $39.2 million in cash for the company he founded in 2015.
He said the March 21 investment will be used to develop a ready-to-use natural killer (NK) cell to treat cancer that could be shipped on an as-needed basis anywhere in the world.
“We have successfully established a truly off-the-shelf, cryopreserved product and are now ready to embark on pivotal trials,” Soon-Shiong said in a statement. “I firmly believe that the natural killer cell represents the missing link in our war against cancer.”
The funds will allow NantKwest, a San Diego-based division of the Culver City-based NantWorks health care conglomerate founded by Soon-Shiong, to launch a phase 2 trial of a combination immunotherapy that employs the natural killer cells to treat Merkel cell carcinoma.
Shares in NantKwest (NK) dipped nearly 2 percent to $1.64 a day after the private placement announcement, with a market cap of $129.7 million.
Health business reporter Dana Bartholomew can be reached at email@example.com. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Soon-Shiong’s NantKwest Launches Clinical Trials for ‘Killer Cells’
- Biotech Mogul Patrick Soon-Shiong to Launch Nant IPO
- Soon-Shiong’s NantKwest Goes Public in $207 Million Offering
- Culver City-Based NantCell Raises $30 Million From Single Investor
- Soon-Shiong Steps Aside as CEO of NantKwest
- Leading L.A. Biotech Companies Post Q3 Losses
- NantKwest Teams With Stem Cell Company on Covid-19 Treatment
- Nanthealth Inc. Reports $175-Million Loss